Immuno-Oncology and Immunotherapeutic Development
Our team of scientists has extensive experience in various cancer models and immuno-oncology studies. We specialize in murine solid tumors for both subcutaneous and orthotopic models, with an emphasis on disease progression, biomarkers and immunophenotyping.
Some examples of our syngeneic cancer models include:
We are able to put any cancer model in place and investigate all immunological and related biomarkers in addition to all cancer-related parameters. Studies to identify the impacts of co-morbidities such as obesity or compounding factors such as the microbiome can be customized.
A metastatic model to study novel immunotherapeutic approaches.
Novel immunotherapeutic approaches have shown efficacy in human renal cell carcinoma (RCC), demonstrating an exciting area of therapeutic potential for this cancer. Renca kidney cancer is a syngeneic, mouse model of metastatic renal cell carcinoma (RCC) in BALB/c mice. Renca cells can be injected subcutaneously or orthotopically. In the orthotopic model, cells are introduced directly into the kidney, wherein they form tumors that metastasize to secondary organs such as the lungs.
Contact Us to receive our presentation of results, discuss your interests and to find out how MD Biosciences expertise could help you obtain your research success.